U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07134205) titled 'The Study of JMT101 Combined With Irinotecan as a >=3rd-Line Treatment in Metastatic Colorectal Cancer' on Aug. 14.
Brief Summary: This is a randomized, open-label, multicenter, phase III clinical study. The aim is to evaluate the efficacy of JMT101 in combination with irinotecan in the third-line and beyond treatment of Metastatic Colorectal Cancer.
Study Start Date: Oct. 01
Study Type: INTERVENTIONAL
Condition:
Metastatic Colorectal Cancer (mCRC)
Intervention:
DRUG: JMT101
JMT101, 6 mg/kg, administered by IV infusion once every two weeks (one treatment cycle is 4 weeks).
DRUG: Irinotecan
Irinotecan, 180mg/m^2, administere...